CLDX Celldex Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 744218 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.9%
TTM net income YoY-37.6%
TTM EPS YoY-26.9%
Revenue 3-yr CAGR-66.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-211,684.8%
Net margin-195,608.9%
FCF margin-164,391.8%
EBITDA margin-209,321.5%
Returns
ROE-49.5%
ROA-45.1%
ROIC (approx.)-44.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue4,915.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.54M | $7.02M |
| Cost of revenue | $200,000 | $200,000 |
| Gross profit | $1.34M | $6.82M |
| R&D expense | $245.07M | $163.55M |
| SG&A expense | $43.84M | $38.55M |
| Operating income | -$287.37M | -$195.08M |
| Pretax income | -$258.76M | -$157.86M |
| Income tax | $0 | $0 |
| Net income | -$258.76M | -$157.86M |
| EBITDA | -$283.99M | -$191.90M |
| EPS (basic) | -3.90 | -2.45 |
| EPS (diluted) | -3.90 | -2.45 |
| Weighted avg. shares (diluted) | 66.42M | 64.39M |
| Balance sheet | ||
| Cash & equivalents | $28.87M | $28.36M |
| Short-term investments | $489.70M | $696.92M |
| Current assets | $534.66M | $747.16M |
| PP&E, net | $5.33M | $4.35M |
| Intangibles | $27.19M | $27.19M |
| Total assets | $582.98M | $792.34M |
| Current liabilities | $50.99M | $39.50M |
| Total liabilities | $55.82M | $45.34M |
| Shareholders' equity | $527.16M | $747.00M |
| Shares outstanding | 66.55M | 66.37M |
| Cash flow statement | ||
| Operating cash flow | -$210.94M | -$157.78M |
| Capital expenditure | $2.71M | $1.92M |
| Free cash flow | -$213.66M | -$159.70M |
| Investing cash flow | $209.07M | -$290.13M |
| Financing cash flow | $2.39M | $441.45M |
| Depreciation & amortization | $3.38M | $3.18M |
| Stock-based compensation | $36.22M | $34.24M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.